{
    "2020-09-19": [
        [
            {
                "time": "2023-10-05",
                "original_text": "Novartis Piqray® data show survival benefit for patients with HR+/HER2- advanced breast cancer with a PIK3CA mutation",
                "features": {
                    "keywords": [
                        "Piqray",
                        "survival benefit",
                        "HR+/HER2-",
                        "advanced breast cancer",
                        "PIK3CA mutation"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Novartis reports late-breaking data from Phase III COMBI-i trial of spartalizumab (PDR001) with Tafinlar® and Mekinist® in advanced melanoma",
                "features": {
                    "keywords": [
                        "Novartis",
                        "COMBI-i trial",
                        "spartalizumab",
                        "Tafinlar",
                        "Mekinist",
                        "advanced melanoma"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}